Market Analysis - Metabolomics Meeting 2017
Metabolomics is an emerging field which combines strategies to identify and quantify cellular metabolites using sophisticated analytical technologies with the application of statistical and multi-variant methods for information extraction and data interpretation. Metabolomics is the study of small metabolites. Metabolomics Conference deals with topics like Bioinformatics, proteomics, systems biology, Analytical Techniques like NMR, GC-MS, LC-MS and CE-MS, Lipidomics, Metabolic Modelling, Metabolic profiling, clinical metabolomics, Translational sciences, Mass spectrometry, Metabolomics Syndrome, HPLC and CE based metabolomics and more. Metabolomics - the new "omics" - is a dynamic and developing field, joining genomics, transcriptomics and proteomics in empowering an integrative frameworks science methodology to drug discovery and development. In spite of the fact that metabolomics is still at an early evolutionary stage it is conjecture that throughout the following decade the biopharma business will apply this innovation all the more generally in drug development and information.
'The Future of Metabolomics' gives fully fledged understanding into the compelling utilization of metabolomics all through drug discovery, preclinical development and clinical trials. The report also highlights the use of metabolomics in maximizing and sustaining revenues post-marketing and in the development of clinical diagnostics.
The National Institutes of Health said that they are to invest $14.3 million for metabolomics research, potentially investing more than $51.4 million over five years, to accelerate an emerging field of biomedical research known as metabolomics. As per National Center for Biotechnology Information. Metabolomics has matured over the past 10 years. Over 300 studies have been completed over the past 5 years.
Global Life Science Market Share by Country
Major Metabolomics Related Associations around the Globe :
American association for the advancement of science
American association for clinical chemistry
American association for cancer research
American association of pharmaceutical scientists
Association for Consumer Research (ACR)
American cancer society
Bioinformatics society of India
The British Society for Genetic Medicine
The Genetics Society
Netherlands metabolomics center
The Australian biotechnology association
Human Proteome Organization
Indiana Proteomics Consortium
European federation of biotechnology
Australasian Proteomics Society
Clinical Genetics Society
Glance at Market of Metabolomics:
The market is mainly driven by the increasing research funding for metabolomics from governments and private investors, growing demand for personalized medicine in the U.S. and Europe, and the increasing need for toxicology testing. However, low adoption rates and data complexity inhibits the growth of the metabolomics market to a certain extent. Metabolomics science is used extensively in biomarker discovery and drug assessment. Thus, the rapid growth experienced by pharmaceutical and biotechnology industries is assisting the growth of the metabolomics market.
In 2013, North America was the market leader with a share of ~42% of the global market, followed by Europe with a share of ~38%. The presence of a large number of analytical equipment manufacturers has contributed significantly to the North American and European metabolomics market. However, the Asia-Pacific region represents a significant growth opportunity for the metabolomics market during the forecast period of 2014 to 2019. The APAC market is expected to grow at a CAGR of 23% during the forecast period. The growth in this market is driven by the growing pharmaceutical and biotechnology industries.
The global metabolomics market was valued at $565 million in 2014 and is expected to grow at a CAGR of 30% from 2014 to 2019.
Statistics which shows growth in importance of Metabolomics :
Metabolomics Market Worth $2,100 Million by 2019 - New Report by Markets and Markets.
Statistics of Industries Associated with Metabolomics :
North America was the market leader with a share of ~42% of the global market, followed by Europe with a share of ~38%. The presence of a large number of analytical equipment manufacturers has contributed significantly to the North American and European metabolomics market. However, the Asia-Pacific region represents a significant growth opportunity for the metabolomics market during the forecast period of 2014 to 2019. The APAC market is expected to grow at a CAGR of 23% during the forecast period. The growth in this market is driven by the growing pharmaceutical and biotechnology industries.
The major players in the metabolomics market include Thermo Fisher Scientific (U.S.), Metabolon, Inc. (U.S.), Danaher Corporation (U.S.), Shimadzu Corporation (Japan), Waters Corporation (U.S.), Agilent Technologies (U.S.), and Bruker Corporation (U.S.).
Fund Allotment towards Metabolomics Research :
The National Institutes of Health has provided tens of millions of dollars in new funding to support three new Comprehensive Metabolomics Centers at Mayo Clinic, the University of Kentucky, and the University of Florida.
These three centers will receive an estimated $9 million to $10 million each over the next five years to create resources and initiate research programs that will ramp up the national metabolomics science capabilities.
NIH provided $14.3 million to fund the launch of three other metabolomics resource centers at the University of Michigan, the Research Triangle Institute, and the University of California, USA
- Michigan Regional Comprehensive Metabolomics Resource Core (MRC2)
- NIH West Coast Metabolomics Center at UC Davis
- Southeast Center for Integrated Metabolomics (SECIM)
- Metabolomics Core at Mayo Clinic
- Research Center for Stable Isotope Resolved Metabolomics
Funding to UC San Diego for this project is $6 million over five years, part of a total investment by the NIH of $51.4 for the metabolomics project. The awards are supported by the NIH Common Fund.
Metabolomic Diagnostics is engaged in a study called IMPROVED, which has received €6m in European FP7 funding.
Mayo Clinic is one of six new federally-funded Comprehensive Metabolomics centres to support medical research on metabolomics — the study, at the cellular level, of how molecules are metabolized in the body. The award from the National Institutes of Health (NIH) is for $8.8 million over five years.
Conference Series LLC welcomes you to attend the 10th International Conference and Exhibition on Metabolomics & Systems Biology during October 19-20, 2017 Baltimore, USA. This is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists. The main theme of the conference is “Metabolomics, a promising approach to Cancer, Cardiovascular disease and immunology”.
Metabolomics Meeting 2017 Conference will be an exploration of New research Innovation of Metabolomics and cover the latest developments and trends in Metabolomics modeling, Proteomics, Systems Biology, Genomics, Precision Medicine, Lipidomics, LC-MS and GC-MS Techniques, Bioinformatics, Plant Metabolomics, Clinical metabolomics, cancer and metabolism, computational biology, metabolomics syndrome, Nutritional Metabolomics, Therapeutic Metabolomics and more. Metabolomics is of interest to physicians because it may lead to improvements in the diagnosis and treatments of human diseases. Conference Series LLC Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide. The global metabolomics market is expected to grow at a strong CAGR during the forecast period of 2014 to 2019 and is estimated to be worth $2,100 million by 2019. The market is mainly driven by the increasing research funding for metabolomics from governments and private investors, growing demand for personalized medicine in the U.S. and Europe, and the increasing need for toxicology testing.